CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
CARsgen Therapeutics was granted orphan drug designation by the US FDA for CAR-T Cells for the treatment of gastric and gastroesophageal junction... Read More
Enhertu granted Priority Review in the US for the treatment of HER2-positive metastatic gastric cancer
AstraZeneca and Daiichi Sankyo were granted priority review by the FDA for Enhertu to treat HER2-positive gastric or gastroesophageal junction cancer, with... Read More
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
The FDA granted fast-track designation to Leap Therapeutics’ DKN-01, which blocks the DKK1 protein found in abundance in some gastric tumors.
Phase 3 Trial Evaluating Opdivo (nivolumab) as Adjuvant Therapy for Patients with Resected Esophageal or Gastroesophageal Junction Cancer, Meets Primary Endpoint of Disease-Free Survival
In a trial, Bristol Myers Squibb’s Opdivo improved disease-free survival in patients with esophageal cancer who had undergone surgery and chemotherapy.
Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
Five Prime Therapeutics’ investigational drug bemarituzumab showed promising efficacy in the late-line treatment of gastroesophageal junction adenocarcinoma.
BeiGene bags option on Leap cancer drug, requests PD-1 combination trial
BeiGene and Leap Therapeutics have teamed up to study a combination of an anti-DKK1 antibody with the anti-PD-1 antibody tislelizumab in patients... Read More
BeiGene bags option on Leap cancer drug, requests PD-1 combination trial
BeiGene and Leap Therapeutics have teamed up to study a combination of an anti-DKK1 antibody with the anti-PD-1 antibody tislelizumab in patients... Read More
Predictors of Response to Immune Checkpoint Inhibitors in Patients With Advanced Esophagogastric Cancer
In a recent trial of checkpoint inhibitors in gastric or esophageal cancer, patients who reported immune-related side effects also showed longer survival... Read More
Oncologie Pairs PS Inhibitor Bavituximab with Merck’s Keytruda for Gastric Cancer
A new clinical trial pairs Oncologie’s bavituximab with Merck’s Keytruda in advanced stomach or gastroesophageal cancer.
Perioperative FOLFIRINOX for Gastroesophageal Adenocarcinoma
In a trial, the chemotherapy regimen FOLFIRINOX produced response rates on par with FLOT and may be easier to tolerate, says Dan... Read More